11:40 AM EST, 11/06/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We adjust our target to $24 from $13, which implies a 2026 P/E of 8.7x. This is a premium to its five-year historical forward average of 4.7x as we expect the "Pivot to Growth" strategy to help support TEVA's growth prospects (versus a declining revenue trend over the past five years). We raise our opinion to Hold from Sell as the removal of a major overhang creates a more balanced risk-reward profile. With the U.S. Inflation Reduction Act (IRA) price negotiations for AUSTEDO now concluded, pricing uncertainty has eased, and the outcome aligned with TEVA's expectations, allowing the company to reiterate its long-term outlook for the drug. That said, risks remain, including the softness in the generics business and ongoing policy risks related to U.S. tariffs on pharmaceuticals. In a tariff environment, we believe the inherently low-margin generics business will become unprofitable.